The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ezmekly (mirdametinib) for the treatment of ...

This article first appeared on GuruFocus. Merck KGaA (NYSE:MRK) is making a fresh push to rebuild its pharmaceutical firepower, and this time it is placing a multibillion-dollar bet on artificial ...

FRANKFURT (Reuters) -Germany's Merck KGaA on Thursday agreed to use Boston-based Valo Health's drug research services in a collaboration focused on Parkinson's and related diseases that is potentially ...

An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...

Europe's universities and research institutes are particularly strong in biotech and pharmaceutical startups. A report from Dealroom shows that since 2022 there have been 244 academic spinouts in ...

Merck KGaA Sponsored ADR ((MKKGY)) has held its Q3 earnings call. Read on for the main highlights of the call. Merck KGaA’s recent earnings call painted a picture of balanced performance, marked by ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

By Annette Bakker The tragedy of rare disease is not only measured in lives lost—it’s also measured in lives that could have ...

Merck & Co. is spending $9.2 billion for Cidara Therapeutics and its lead influenza antiviral that was dropped by Johnson & Johnson last year. Merck is paying $221.50 cash per share of Cidara, a San ...

Nov 14 (Reuters) - Merck (MRK.N), opens new tab will acquire Cidara Therapeutics (CDTX.O), opens new tab in a nearly $9.2 billion deal, gaining access to an experimental flu drug in its effort to ...